RELMADA THERAPEUTICS, INC. (RLMD) Form 8-K — Aug 6, 2026
Relmada Therapeutics reported second quarter 2026 results on August 6, 2026, posting a net loss of $12.9 million, or $0.11 per share, versus a $9.9 million loss ($0.30 per share) a year earlier. R&D expense more than tripled to $8.4 million from $2.8 million on higher NDV-01 and sepranolone study, manufacturing, and drug storage costs, while G&A declined to $6.6 million from $7.4 million. The balance sheet strengthened materially: cash, cash equivalents and short-term investments reached $217.7 million at June 30, 2026, up from roughly $93.0 million at year-end 2025 after a roughly $160 million equity raise during the half.
Key figures
- Guidance
- Cash, cash equivalents and short-term investments of $217.7 million expected to fund operations through 2029, including completion of the Phase 3 NDV-01 RESCUE program
- Total Assets
- 219059177
- Shares Outstanding
- 106669846
- Cash Runway
- through 2029
- Ga Expense Q2 2025
- 7401929
- Ga Expense Q2 2026
- 6617238
- Total Liabilities
- 12500854
- Rnd Expense Q2 2025
- 2819377
- Rnd Expense Q2 2026
- 8393789
- Stock Issuance Fees
- 9817890
- Trcg011 12 Month CR
- 76% (83% KM analysis); 95% anytime CR
- Stockholders Equity
- 206558323
- Ndv01 Ind Filing Target
- By YE26
- Ph3 Rescue Cohort1 target N
- 276
- Weighted Avg Shares Q2 2026
- 112375941
- Ph3 Rescue Cohort2 A target N
- 87
- Sepranolone Ind Filing Target
- By YE26
- Net Cash Used Operating Q2 2026
- $9.6 million
- Proceeds From Stock Issuance Six Months 2026
- 159999996
Price after filing
Close on the filing date to close N calendar days later (from $5.47). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.